Publications
999 found
Show per page
Oh, J., Capezzuto, L., Kriara, L., Schjodt-Eriksen, J., van Beek, J., Bernasconi, C., Montalban, X., Butzkueven, H., Kappos, L., Giovannoni, G., Bove, R., Julian, L., Baker, M., Gossens, C., & Lindemann, M. (2024). Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-023-49299-4
Oh, J., Capezzuto, L., Kriara, L., Schjodt-Eriksen, J., van Beek, J., Bernasconi, C., Montalban, X., Butzkueven, H., Kappos, L., Giovannoni, G., Bove, R., Julian, L., Baker, M., Gossens, C., & Lindemann, M. (2024). Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access study. Scientific Reports, 14(1). https://doi.org/10.1038/s41598-023-49299-4
Ciccarelli, O., Barkhof, F., Calabrese, M., De Stefano, N., Eshaghi, A., Filippi, M., Gasperini, C., Granziera, C., Kappos, L., Rocca, M. A., Rovira, À., Sastre-Garriga, J., Sormani, M. P., Tur, C., & Toosy, A. T. (2024). Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis [Journal-article]. Neurology, 103(1). https://doi.org/10.1212/wnl.0000000000209444
Ciccarelli, O., Barkhof, F., Calabrese, M., De Stefano, N., Eshaghi, A., Filippi, M., Gasperini, C., Granziera, C., Kappos, L., Rocca, M. A., Rovira, À., Sastre-Garriga, J., Sormani, M. P., Tur, C., & Toosy, A. T. (2024). Using the Progression Independent of Relapse Activity Framework to Unveil the Pathobiological Foundations of Multiple Sclerosis [Journal-article]. Neurology, 103(1). https://doi.org/10.1212/wnl.0000000000209444
Chitnis, T., Banwell, B., Kappos, L., Arnold, D. L., Gücüyener, K., Deiva, K., Saubadu, S., Hu, W., Benamor, M., Le-Halpere, A., Truffinet, P., & Tardieu, M. (2024). Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS. Multiple Sclerosis Journal, 30(7), 833–842. https://doi.org/10.1177/13524585241242050
Chitnis, T., Banwell, B., Kappos, L., Arnold, D. L., Gücüyener, K., Deiva, K., Saubadu, S., Hu, W., Benamor, M., Le-Halpere, A., Truffinet, P., & Tardieu, M. (2024). Teriflunomide in pediatric patients with relapsing multiple sclerosis: Open-label extension of TERIKIDS. Multiple Sclerosis Journal, 30(7), 833–842. https://doi.org/10.1177/13524585241242050
Fox, R. J., Cree, B. A. C., de Sèze, J., Gold, R., Hartung, H.-P., Jeffery, D., Kappos, L., Montalban, X., Weinstock-Guttman, B., Singh, C. M., Altincatal, A., Belviso, N., Avila, R. L., Ho, P.-R., Su, R., Engle, R., Sangurdekar, D., de Moor, C., Fisher, E., et al. (2024). Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis. Neurology, 102(9). https://doi.org/10.1212/wnl.0000000000209357
Fox, R. J., Cree, B. A. C., de Sèze, J., Gold, R., Hartung, H.-P., Jeffery, D., Kappos, L., Montalban, X., Weinstock-Guttman, B., Singh, C. M., Altincatal, A., Belviso, N., Avila, R. L., Ho, P.-R., Su, R., Engle, R., Sangurdekar, D., de Moor, C., Fisher, E., et al. (2024). Temporal Relationship Between Serum Neurofilament Light Chain and Radiologic Disease Activity in Patients With Multiple Sclerosis. Neurology, 102(9). https://doi.org/10.1212/wnl.0000000000209357
Woelfle, T., Hirt, J., Janiaud, P., Kappos, L., Ioannidis, J. P. A., & Hemkens, L. G. (2024). Benchmarking Human-AI Collaboration for Common Evidence Appraisal Tools [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.04.21.24306137
Woelfle, T., Hirt, J., Janiaud, P., Kappos, L., Ioannidis, J. P. A., & Hemkens, L. G. (2024). Benchmarking Human-AI Collaboration for Common Evidence Appraisal Tools [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.04.21.24306137
Weigel, M., Dechent, P., Galbusera, R., Bahn, E., Lu, P.-J., Kappos, L., Brück, W., Stadelmann, C., & Granziera, C. (2024). Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.04.18.589707
Weigel, M., Dechent, P., Galbusera, R., Bahn, E., Lu, P.-J., Kappos, L., Brück, W., Stadelmann, C., & Granziera, C. (2024). Cerebellar Ex Vivo Magnetic Resonance Imaging at its Feasibility Limit: Up to 77-Microns Isotropic Resolution using Low-Bandwidth Balanced Steady State Free Precession (LoBa-bSSFP) Sequences and 3T Standard Equipment [Posted-content]. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.04.18.589707
Janiaud, Perrine, Zecca, Chiara, Salmen, Anke, Benkert, Pascal, Schädelin, Sabine, Orleth, Annette, Demuth, Lilian, Maceski, Aleksandra Maleska, Granziera, Cristina, Oechtering, Johanna, Leppert, David, Derfuss, Tobias, Achtnichts, Lutz, Findling, Oliver, Roth, Patrick, Lalive, Patrice, Uginet, Marjolaine, Müller, Stefanie, Pot, Caroline, et al. (2024). MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial [Posted-content]. In medRxiv. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.03.22.24304720
Janiaud, Perrine, Zecca, Chiara, Salmen, Anke, Benkert, Pascal, Schädelin, Sabine, Orleth, Annette, Demuth, Lilian, Maceski, Aleksandra Maleska, Granziera, Cristina, Oechtering, Johanna, Leppert, David, Derfuss, Tobias, Achtnichts, Lutz, Findling, Oliver, Roth, Patrick, Lalive, Patrice, Uginet, Marjolaine, Müller, Stefanie, Pot, Caroline, et al. (2024). MultiSCRIPT-Cycle 1- A Pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in Multiple Sclerosis: a study protocol for a randomized clinical trial [Posted-content]. In medRxiv. Cold Spring Harbor Laboratory. https://doi.org/10.1101/2024.03.22.24304720
Cagol, Alessandro, Benkert, Pascal, Melie-Garcia, Lester, Schaedelin, Sabine A., Leber, Selina, Tsagkas, Charidimos, Barakovic, Muhamed, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Ruberte, Esther, Radue, Ernst-Wilhelm, Yaldizli, Özgür, Oechtering, Johanna, Lorscheider, Johannes, D’Souza, Marcus, Fischer-Barnicol, Bettina, Muller, Stefanie, Achtnichts, Lutz, et al. (2024). Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. Neurology, 102. https://doi.org/10.1212/wnl.0000000000207768
Cagol, Alessandro, Benkert, Pascal, Melie-Garcia, Lester, Schaedelin, Sabine A., Leber, Selina, Tsagkas, Charidimos, Barakovic, Muhamed, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Ruberte, Esther, Radue, Ernst-Wilhelm, Yaldizli, Özgür, Oechtering, Johanna, Lorscheider, Johannes, D’Souza, Marcus, Fischer-Barnicol, Bettina, Muller, Stefanie, Achtnichts, Lutz, et al. (2024). Association of Spinal Cord Atrophy and Brain Paramagnetic Rim Lesions With Progression Independent of Relapse Activity in People With MS. Neurology, 102. https://doi.org/10.1212/wnl.0000000000207768
Derfuss, T., Bermel, R., Lin, C.-J., Hauser, S. L., Kappos, L., Vollmer, T., Comi, G., Giovannoni, G., Hartung, H.-P., Weber, M. S., Wang, J., Jessop, N., Chognot, C., Craveiro, L., & Bar-Or, A. (2024). Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials [Journal-article]. Therapeutic Advances in Neurological Disorders, 17. https://doi.org/10.1177/17562864241277736
Derfuss, T., Bermel, R., Lin, C.-J., Hauser, S. L., Kappos, L., Vollmer, T., Comi, G., Giovannoni, G., Hartung, H.-P., Weber, M. S., Wang, J., Jessop, N., Chognot, C., Craveiro, L., & Bar-Or, A. (2024). Long-term analysis of infections and associated risk factors in patients with multiple sclerosis treated with ocrelizumab: pooled analysis of 13 interventional clinical trials [Journal-article]. Therapeutic Advances in Neurological Disorders, 17. https://doi.org/10.1177/17562864241277736
Galbusera, Riccardo, Bahn, Erik, Weigel, Matthias, Cagol, Alessandro, Lu, Po-Jui, Schaedelin, Sabine A., Franz, Jonas, Barakovic, Muhamed, Rahmanzadeh, Reza, Dechent, Peter, Nair, Govind, Brück, Wolfgang, Kuhle, Jens, Neurology, 102, e207966. https://doi.org/10.1212/wnl.0000000000207966
, Stadelmann, Christine, & Granziera, Cristina. (2024). Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
Galbusera, Riccardo, Bahn, Erik, Weigel, Matthias, Cagol, Alessandro, Lu, Po-Jui, Schaedelin, Sabine A., Franz, Jonas, Barakovic, Muhamed, Rahmanzadeh, Reza, Dechent, Peter, Nair, Govind, Brück, Wolfgang, Kuhle, Jens, Neurology, 102, e207966. https://doi.org/10.1212/wnl.0000000000207966
, Stadelmann, Christine, & Granziera, Cristina. (2024). Characteristics, Prevalence, and Clinical Relevance of Juxtacortical Paramagnetic Rims in Patients With Multiple Sclerosis.
Gloor M, Andelova M, Gaetano L, Papadopoulou A, Burguet Villena F, Sprenger T, Radue EW, European Society of Radiology. https://doi.org/10.1007/s00330-023-10173-6
, Bieri O, & Garcia M. (2024). Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging.
Gloor M, Andelova M, Gaetano L, Papadopoulou A, Burguet Villena F, Sprenger T, Radue EW, European Society of Radiology. https://doi.org/10.1007/s00330-023-10173-6
, Bieri O, & Garcia M. (2024). Longitudinal analysis of new multiple sclerosis lesions with magnetization transfer and diffusion tensor imaging.
Greselin, Martina, Lu, Po-Jui, Melie-Garcia, Lester, Ocampo-Pineda, Mario, Galbusera, Riccardo, Cagol, Alessandro, Weigel, Matthias, de Oliveira Siebenborn, Nina, Ruberte, Esther, Benkert, Pascal, Müller, Stefanie, Finkener, Sebastian, Vehoff, Jochen, Disanto, Giulio, Findling, Oliver, Chan, Andrew, Salmen, Anke, Pot, Caroline, Bridel, Claire, et al. (2024). Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort [Journal-article]. Bioengineering, 11(8), 858. https://doi.org/10.3390/bioengineering11080858
Greselin, Martina, Lu, Po-Jui, Melie-Garcia, Lester, Ocampo-Pineda, Mario, Galbusera, Riccardo, Cagol, Alessandro, Weigel, Matthias, de Oliveira Siebenborn, Nina, Ruberte, Esther, Benkert, Pascal, Müller, Stefanie, Finkener, Sebastian, Vehoff, Jochen, Disanto, Giulio, Findling, Oliver, Chan, Andrew, Salmen, Anke, Pot, Caroline, Bridel, Claire, et al. (2024). Contrast-Enhancing Lesion Segmentation in Multiple Sclerosis: A Deep Learning Approach Validated in a Multicentric Cohort [Journal-article]. Bioengineering, 11(8), 858. https://doi.org/10.3390/bioengineering11080858
Hirt, Julian, Dembowska, Kinga, Woelfle, Tim, Axfors, Cathrine, Granziera, Cristina, Kuhle, Jens, Journal of Neurology. https://doi.org/10.1007/s00415-024-12366-5
, Hemkens, Lars G., & Janiaud, Perrine. (2024). Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
Hirt, Julian, Dembowska, Kinga, Woelfle, Tim, Axfors, Cathrine, Granziera, Cristina, Kuhle, Jens, Journal of Neurology. https://doi.org/10.1007/s00415-024-12366-5
, Hemkens, Lars G., & Janiaud, Perrine. (2024). Clinical trial evidence of quality-of-life effects of disease-modifying therapies for multiple sclerosis: a systematic analysis.
Hirt, Julian, Janiaud, Perrine, Düblin, Pascal, Nicoletti, Giovanni Jacopo, Dembowska, Kinga, Nguyen, Thao Vy Thi, Woelfle, Tim, Axfors, Cathrine, Yaldizli, Özgür, Granziera, Cristina, Kuhle, Jens, Multiple Sclerosis Journal, 30, 463–478. https://doi.org/10.1177/13524585231221938
, & Hemkens, Lars G. (2024). Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
Hirt, Julian, Janiaud, Perrine, Düblin, Pascal, Nicoletti, Giovanni Jacopo, Dembowska, Kinga, Nguyen, Thao Vy Thi, Woelfle, Tim, Axfors, Cathrine, Yaldizli, Özgür, Granziera, Cristina, Kuhle, Jens, Multiple Sclerosis Journal, 30, 463–478. https://doi.org/10.1177/13524585231221938
, & Hemkens, Lars G. (2024). Use of pragmatic randomized trials in multiple sclerosis: A systematic overview.
Janiaud, Perrine, Zecca, Chiara, Salmen, Anke, Benkert, Pascal, Schädelin, Sabine, Orleth, Annette, Demuth, Lilian, Maceski, Aleksandra Maleska, Granziera, Cristina, Oechtering, Johanna, Leppert, David, Derfuss, Tobias, Achtnichts, Lutz, Findling, Oliver, Roth, Patrick, Lalive, Patrice, Uginet, Marjolaine, Müller, Stefanie, Pot, Caroline, et al. (2024). MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial. Trials, 25. https://doi.org/10.1186/s13063-024-08454-6
Janiaud, Perrine, Zecca, Chiara, Salmen, Anke, Benkert, Pascal, Schädelin, Sabine, Orleth, Annette, Demuth, Lilian, Maceski, Aleksandra Maleska, Granziera, Cristina, Oechtering, Johanna, Leppert, David, Derfuss, Tobias, Achtnichts, Lutz, Findling, Oliver, Roth, Patrick, Lalive, Patrice, Uginet, Marjolaine, Müller, Stefanie, Pot, Caroline, et al. (2024). MultiSCRIPT-Cycle 1—a pragmatic trial embedded within the Swiss Multiple Sclerosis Cohort (SMSC) on neurofilament light chain monitoring to inform personalized treatment decisions in multiple sclerosis: a study protocol for a randomized clinical trial. Trials, 25. https://doi.org/10.1186/s13063-024-08454-6
Kappos, L., Edan, G., Freedman, M. S., Hartung, H.-P., Montalbán, X., Barkhof, F., Koelbach, R., MacManus, D. G., & Wicklein, E.-M. (2024). Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. Journal of Neurology. https://doi.org/10.1007/s00415-024-12417-x
Kappos, L., Edan, G., Freedman, M. S., Hartung, H.-P., Montalbán, X., Barkhof, F., Koelbach, R., MacManus, D. G., & Wicklein, E.-M. (2024). Long-term clinical outcomes in patients with CIS treated with interferon beta-1b: results from the 15-year follow up of the BENEFIT trial. Journal of Neurology. https://doi.org/10.1007/s00415-024-12417-x
Journal of Neurology, 271, 642–657. https://doi.org/10.1007/s00415-023-11943-4
, Traboulsee, Anthony, Li, David K. B., Bar-Or, Amit, Barkhof, Frederik, Montalban, Xavier, Leppert, David, Baldinotti, Anna, Schneble, Hans-Martin, Koendgen, Harold, Sauter, Annette, Wang, Qing, & Hauser, Stephen L. (2024). Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Journal of Neurology, 271, 642–657. https://doi.org/10.1007/s00415-023-11943-4
, Traboulsee, Anthony, Li, David K. B., Bar-Or, Amit, Barkhof, Frederik, Montalban, Xavier, Leppert, David, Baldinotti, Anna, Schneble, Hans-Martin, Koendgen, Harold, Sauter, Annette, Wang, Qing, & Hauser, Stephen L. (2024). Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Müller, Jannis, Lu, Po-Jui, Cagol, Alessandro, Ruberte, Esther, Shin, Hyeong-Geol, Ocampo-Pineda, Mario, Chen, Xinjie, Tsagkas, Charidimos, Barakovic, Muhamed, Galbusera, Riccardo, Weigel, Matthias, Schaedelin, Sabine A., Wang, Yi, Nguyen, Thanh D., Spincemaille, Pascal, Neurology, 103(6). https://doi.org/10.1212/WNL.0000000000209604
, Kuhle, Jens, Lee, Jongho, & Granziera, Cristina. (2024). Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions [Journal-article].
Müller, Jannis, Lu, Po-Jui, Cagol, Alessandro, Ruberte, Esther, Shin, Hyeong-Geol, Ocampo-Pineda, Mario, Chen, Xinjie, Tsagkas, Charidimos, Barakovic, Muhamed, Galbusera, Riccardo, Weigel, Matthias, Schaedelin, Sabine A., Wang, Yi, Nguyen, Thanh D., Spincemaille, Pascal, Neurology, 103(6). https://doi.org/10.1212/WNL.0000000000209604
, Kuhle, Jens, Lee, Jongho, & Granziera, Cristina. (2024). Quantifying Remyelination Using χ-Separation in White Matter and Cortical Multiple Sclerosis Lesions [Journal-article].
Hauser S.L., Neurology and Therapy, 12(5), 1491–1515. https://doi.org/10.1007/s40120-023-00518-0
, Bar-Or A., Wiendl H., Paling D., Williams M., Gold R., Chan A., Milo R., Das Gupta A., Karlsson G., Sullivan R., Graham G., Merschhemke M., Haring D.A., & Vermersch P. (2023). The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser S.L., Neurology and Therapy, 12(5), 1491–1515. https://doi.org/10.1007/s40120-023-00518-0
, Bar-Or A., Wiendl H., Paling D., Williams M., Gold R., Chan A., Milo R., Das Gupta A., Karlsson G., Sullivan R., Graham G., Merschhemke M., Haring D.A., & Vermersch P. (2023). The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.
Hauser, S. L., Zielman, R., Das Gupta, A., Xi, J., Stoneman, D., Karlsson, G., Robertson, D., Cohen, J. A., & Kappos, L. (2023). Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. Multiple Sclerosis Journal, 29(11-12), 1452–1464. https://doi.org/10.1177/13524585231195346
Hauser, S. L., Zielman, R., Das Gupta, A., Xi, J., Stoneman, D., Karlsson, G., Robertson, D., Cohen, J. A., & Kappos, L. (2023). Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: The ALITHIOS open-label extension. Multiple Sclerosis Journal, 29(11-12), 1452–1464. https://doi.org/10.1177/13524585231195346
Woelfle T, Bourguignon L, Lorscheider J, Journal of Medical Internet Research, 25, e44428. https://doi.org/10.2196/44428
, Naegelin Y, & Jutzeler CR. (2023). Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective.
Woelfle T, Bourguignon L, Lorscheider J, Journal of Medical Internet Research, 25, e44428. https://doi.org/10.2196/44428
, Naegelin Y, & Jutzeler CR. (2023). Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective.
Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Duquette P, Terzi M, Boz C, Grand’Maison F, Sola P, et al. (2023). Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Journal of Neurology, Neurosurgery, and Psychiatry. https://doi.org/10.1136/jnnp-2023-331499
Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Duquette P, Terzi M, Boz C, Grand’Maison F, Sola P, et al. (2023). Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Journal of Neurology, Neurosurgery, and Psychiatry. https://doi.org/10.1136/jnnp-2023-331499
Pless S, Woelfle T, Naegelin Y, Lorscheider J, Wiencierz A, Reyes Ó, Calabrese P, & Journal of Neurology, 270(7), 3451–3463. https://doi.org/10.1007/s00415-023-11671-9
. (2023). Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
Pless S, Woelfle T, Naegelin Y, Lorscheider J, Wiencierz A, Reyes Ó, Calabrese P, & Journal of Neurology, 270(7), 3451–3463. https://doi.org/10.1007/s00415-023-11671-9
. (2023). Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.
Cortese R., Battaglini M., Prados F., Bianchi A., Haider L., Jacob A., Palace J, Messina S., Paul F, Wuerfel J., Marignier R., Durand-Dubief F., de Medeiros Rimkus C., Callegaro D., Sato D.K., Filippi M, Rocca MA, Cacciaguerra L., Rovira A, et al. (2023). Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain, 146(6), 2489–2501. https://doi.org/10.1093/brain/awac480
Cortese R., Battaglini M., Prados F., Bianchi A., Haider L., Jacob A., Palace J, Messina S., Paul F, Wuerfel J., Marignier R., Durand-Dubief F., de Medeiros Rimkus C., Callegaro D., Sato D.K., Filippi M, Rocca MA, Cacciaguerra L., Rovira A, et al. (2023). Clinical and MRI measures to identify non-acute MOG-antibody disease in adults. Brain, 146(6), 2489–2501. https://doi.org/10.1093/brain/awac480
Pfeuffer S., Rolfes L., Ingwersen J., Pul R., Kleinschnitz K., Korsen M., Rauber S., Ruck T., Schieferdecker S., Willison A.G., Aktas O., Kleinschnitz C., Hartung H.-P., Neurology(R) Neuroimmunology & Neuroinflammation, 10(3). https://doi.org/10.1212/nxi.0000000000200104
, & Meuth S.G. (2023). Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Pfeuffer S., Rolfes L., Ingwersen J., Pul R., Kleinschnitz K., Korsen M., Rauber S., Ruck T., Schieferdecker S., Willison A.G., Aktas O., Kleinschnitz C., Hartung H.-P., Neurology(R) Neuroimmunology & Neuroinflammation, 10(3). https://doi.org/10.1212/nxi.0000000000200104
, & Meuth S.G. (2023). Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
Cagol A., Fuertes N.C., Stoessel M., Barakovic M., Schaedelin S., D’Souza M, Wurfel J., Brandt A.U., Journal of Neurology, 270(4), 2139–2148. https://doi.org/10.1007/s00415-022-11535-8
, Sprenger T, Naegelin Y, Kuhle J, Granziera C, & Papadopoulou A. (2023). Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
Cagol A., Fuertes N.C., Stoessel M., Barakovic M., Schaedelin S., D’Souza M, Wurfel J., Brandt A.U., Journal of Neurology, 270(4), 2139–2148. https://doi.org/10.1007/s00415-022-11535-8
, Sprenger T, Naegelin Y, Kuhle J, Granziera C, & Papadopoulou A. (2023). Optical coherence tomography reflects clinically relevant gray matter damage in patients with multiple sclerosis.
Diouf I., Malpas C.B., Sharmin S., Roos I., Horakova D., Havrdova E.K., Patti F., Shaygannejad V., Ozakbas S., Izquierdo G., Eichau S., Onofrj M., Lugaresi A., Alroughani R., Prat A., Girard M., Duquette P., Terzi M., Boz C., et al. (2023). Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology, 30(4), 1014–1024. https://doi.org/10.1111/ene.15706
Diouf I., Malpas C.B., Sharmin S., Roos I., Horakova D., Havrdova E.K., Patti F., Shaygannejad V., Ozakbas S., Izquierdo G., Eichau S., Onofrj M., Lugaresi A., Alroughani R., Prat A., Girard M., Duquette P., Terzi M., Boz C., et al. (2023). Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology, 30(4), 1014–1024. https://doi.org/10.1111/ene.15706
Vrenken H., Battaglini M., de Vos M.L., Nagtegaal G.J., Teixeira B.C.A., Seitzinger A., Jack D., Sormani M.P., Uitdehaag B.M.J., Versteeg A., Comi G., Journal of Neurology, 270(4), 2271–2282. https://doi.org/10.1007/s00415-022-11554-5
, De Stefano N., & Barkhof F. (2023). Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.
Vrenken H., Battaglini M., de Vos M.L., Nagtegaal G.J., Teixeira B.C.A., Seitzinger A., Jack D., Sormani M.P., Uitdehaag B.M.J., Versteeg A., Comi G., Journal of Neurology, 270(4), 2271–2282. https://doi.org/10.1007/s00415-022-11554-5
, De Stefano N., & Barkhof F. (2023). Temporal evolution of new T1-weighted hypo-intense lesions and central brain atrophy in patients with a first clinical demyelinating event treated with subcutaneous interferon β-1a.
Hauser S.L., Bar-Or A., Weber M.S., Kletzl H., Gunther A., Manfrini M., Model F., Mercier F., Petry C., Wing Q., Koendgen H., Smith T., & Neurology: Neuroimmunology and NeuroInflammation, 10(2). https://doi.org/10.1212/nxi.0000000000200094
(2023). Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser S.L., Bar-Or A., Weber M.S., Kletzl H., Gunther A., Manfrini M., Model F., Mercier F., Petry C., Wing Q., Koendgen H., Smith T., & Neurology: Neuroimmunology and NeuroInflammation, 10(2). https://doi.org/10.1212/nxi.0000000000200094
(2023). Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Kuhle J, Chitnis T., Banwell B., Tardieu M., Arnold DL, Rawlings A.M., Geertsen S.S., Lublin AL, Saubadu S., Truffinet P., & Multiple Sclerosis Journal, 29(3), 385–394. https://doi.org/10.1177/13524585221144742
(2023). Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Kuhle J, Chitnis T., Banwell B., Tardieu M., Arnold DL, Rawlings A.M., Geertsen S.S., Lublin AL, Saubadu S., Truffinet P., & Multiple Sclerosis Journal, 29(3), 385–394. https://doi.org/10.1177/13524585221144742
(2023). Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial.
Tsagkas, Charidimos, Huck-Horvath, Antal, Cagol, Alessandro, Haas, Tanja, Amann, Michael, Barakovic, Muhamed, Ruberte, Esther, Melie-Garcia, Lester, Weigel, Matthias, Pezold, Simon, Schlaeger, Regina, Kuhle, Jens, Sprenger, Till, Multiple Sclerosis and Related Disorders, 71, 104545. https://doi.org/10.1016/j.msard.2023.104545
, Bieri, Oliver, Cattin, Philippe, Granziera, Cristina, & Parmar, Katrin. (2023). Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis [Journal-article].
Tsagkas, Charidimos, Huck-Horvath, Antal, Cagol, Alessandro, Haas, Tanja, Amann, Michael, Barakovic, Muhamed, Ruberte, Esther, Melie-Garcia, Lester, Weigel, Matthias, Pezold, Simon, Schlaeger, Regina, Kuhle, Jens, Sprenger, Till, Multiple Sclerosis and Related Disorders, 71, 104545. https://doi.org/10.1016/j.msard.2023.104545
, Bieri, Oliver, Cattin, Philippe, Granziera, Cristina, & Parmar, Katrin. (2023). Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis [Journal-article].
Tsagkas C, Huck-Horvath A, Cagol A, Haas T, Amann M, Barakovic M, Ruberte E, Melie-Garcia L, Weigel M, Pezold S, Schlaeger R, Kuhle J, Sprenger T, Multiple Sclerosis and Related Disorders, 71, 104545. https://doi.org/10.1016/j.msard.2023.104545
, Bieri O, Cattin P, Granziera C, & Parmar K. (2023). Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis.
Tsagkas C, Huck-Horvath A, Cagol A, Haas T, Amann M, Barakovic M, Ruberte E, Melie-Garcia L, Weigel M, Pezold S, Schlaeger R, Kuhle J, Sprenger T, Multiple Sclerosis and Related Disorders, 71, 104545. https://doi.org/10.1016/j.msard.2023.104545
, Bieri O, Cattin P, Granziera C, & Parmar K. (2023). Longitudinal assessment of cervical spinal cord compartments in multiple sclerosis.
Tsagkas C, Horvath-Huck A, Haas T, Amann M, Todea A, Altermatt A, Müller J, Cagol A, Leimbacher M, Barakovic M, Weigel M, Pezold S, Sprenger T, AJNR. American Journal of Neuroradiology, 44(2), 218–227. https://doi.org/10.3174/ajnr.a7756
, Bieri O, Granziera C, Cattin P, & Parmar K. (2023). Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis.
Tsagkas C, Horvath-Huck A, Haas T, Amann M, Todea A, Altermatt A, Müller J, Cagol A, Leimbacher M, Barakovic M, Weigel M, Pezold S, Sprenger T, AJNR. American Journal of Neuroradiology, 44(2), 218–227. https://doi.org/10.3174/ajnr.a7756
, Bieri O, Granziera C, Cattin P, & Parmar K. (2023). Fully Automatic Method for Reliable Spinal Cord Compartment Segmentation in Multiple Sclerosis.
Ziemssen T., Bhan V., Chataway J., Chitnis T., Campbell Cree B.A., Havrdova E.K., Neurology: Neuroimmunology and NeuroInflammation, 10(1). https://doi.org/10.1212/nxi.0000000000200064
, Labauge P., Miller A., Nakahara J., Oreja-Guevara C., Palace J., Singer B., Trojano M., Patil A., Rauser B., & Hach T. (2023). Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Ziemssen T., Bhan V., Chataway J., Chitnis T., Campbell Cree B.A., Havrdova E.K., Neurology: Neuroimmunology and NeuroInflammation, 10(1). https://doi.org/10.1212/nxi.0000000000200064
, Labauge P., Miller A., Nakahara J., Oreja-Guevara C., Palace J., Singer B., Trojano M., Patil A., Rauser B., & Hach T. (2023). Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Abdelhak, Ahmed, Benkert, Pascal, Schaedelin, Sabine, Boscardin, W. John, Cordano, Christian, Oechtering, Johanna, Ananth, Kirtana, Granziera, Cristina, Melie-Garcia, Lester, Montes, Shivany Condor, Beaudry-Richard, Alexandra, Achtnichts, Lutz, Oertel, Frederike C., Lalive, Patrice H., Leppert, David, Müller, Stefanie, Henry, Roland G., Pot, Caroline, Matthias, Amandine, et al. (2023). Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. JAMA Neurology, 80, 1317–1325. https://doi.org/10.1001/jamaneurol.2023.3997
Abdelhak, Ahmed, Benkert, Pascal, Schaedelin, Sabine, Boscardin, W. John, Cordano, Christian, Oechtering, Johanna, Ananth, Kirtana, Granziera, Cristina, Melie-Garcia, Lester, Montes, Shivany Condor, Beaudry-Richard, Alexandra, Achtnichts, Lutz, Oertel, Frederike C., Lalive, Patrice H., Leppert, David, Müller, Stefanie, Henry, Roland G., Pot, Caroline, Matthias, Amandine, et al. (2023). Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. JAMA Neurology, 80, 1317–1325. https://doi.org/10.1001/jamaneurol.2023.3997
Abdelhak, Ahmed, Petermeier, Franziska, Benkert, Pascal, Schädelin, Sabine, Oechtering, Johanna, Maleska Maceski, Aleksandra, Kabesch, Michael, Geis, Tobias, Laub, Otto, Leipold, Georg, Gobbi, Claudio, Zecca, Chiara, Green, Ari, Tumani, Hayrettin, Willemse, Eline, Wiendl, Heinz, Granziera, Cristina, The Lancet Neurology, 22, 826–833. https://doi.org/10.1016/s1474-4422(23)00210-7
, Leppert, David, et al. (2023). Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study.
Abdelhak, Ahmed, Petermeier, Franziska, Benkert, Pascal, Schädelin, Sabine, Oechtering, Johanna, Maleska Maceski, Aleksandra, Kabesch, Michael, Geis, Tobias, Laub, Otto, Leipold, Georg, Gobbi, Claudio, Zecca, Chiara, Green, Ari, Tumani, Hayrettin, Willemse, Eline, Wiendl, Heinz, Granziera, Cristina, The Lancet Neurology, 22, 826–833. https://doi.org/10.1016/s1474-4422(23)00210-7
, Leppert, David, et al. (2023). Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study.
Ayroza Galvão Ribeiro Gomes, Ana Beatriz, Kulsvehagen, Laila, Lipps, Patrick, Cagol, Alessandro, Cerdá-Fuertes, Nuria, Neziraj, Tradite, Flammer, Julia, Lerner, Jasmine, Lecourt, Anne-Catherine, De Oliveira S. Siebenborn, Nina, Cortese, Rosa, Schaedelin, Sabine, Andreoli Schoeps, Vinicius, De Moura Brasil Matos, Aline, Trombini Mendes, Natalia, Dos Reis Pereira, Clarissa, Ribeiro Monteiro, Mario Luiz, Dos Apóstolos-Pereira, Samira Luisa, Schindler, Patrick, et al. (2023). Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients with Central Nervous System Demyelination. JAMA Neurology, 80, 989–995. https://doi.org/10.1001/jamaneurol.2023.2523
Ayroza Galvão Ribeiro Gomes, Ana Beatriz, Kulsvehagen, Laila, Lipps, Patrick, Cagol, Alessandro, Cerdá-Fuertes, Nuria, Neziraj, Tradite, Flammer, Julia, Lerner, Jasmine, Lecourt, Anne-Catherine, De Oliveira S. Siebenborn, Nina, Cortese, Rosa, Schaedelin, Sabine, Andreoli Schoeps, Vinicius, De Moura Brasil Matos, Aline, Trombini Mendes, Natalia, Dos Reis Pereira, Clarissa, Ribeiro Monteiro, Mario Luiz, Dos Apóstolos-Pereira, Samira Luisa, Schindler, Patrick, et al. (2023). Immunoglobulin A Antibodies Against Myelin Oligodendrocyte Glycoprotein in a Subgroup of Patients with Central Nervous System Demyelination. JAMA Neurology, 80, 989–995. https://doi.org/10.1001/jamaneurol.2023.2523
Bar-Or, Amit, Thanei, Gian-Andrea, Harp, Christopher, Bernasconi, Corrado, Bonati, Ulrike, Cross, Anne H., Fischer, Saloumeh, Gaetano, Laura, Hauser, Stephen L., Hendricks, Robert, eBioMedicine, 93. https://doi.org/10.1016/j.ebiom.2023.104662
, Kuhle, Jens, Leppert, David, Model, Fabian, Sauter, Annette, Koendgen, Harold, Jia, Xiaoming, & Herman, Ann E. (2023). Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or, Amit, Thanei, Gian-Andrea, Harp, Christopher, Bernasconi, Corrado, Bonati, Ulrike, Cross, Anne H., Fischer, Saloumeh, Gaetano, Laura, Hauser, Stephen L., Hendricks, Robert, eBioMedicine, 93. https://doi.org/10.1016/j.ebiom.2023.104662
, Kuhle, Jens, Leppert, David, Model, Fabian, Sauter, Annette, Koendgen, Harold, Jia, Xiaoming, & Herman, Ann E. (2023). Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bühler A, Wolbers M, Model F, Wang Q, Belachew S, Manfrini M, Lorscheider J, Multiple Sclerosis (Houndmills, Basingstoke, England), 29(1), 130–139. https://doi.org/10.1177/13524585221125382
, & Beyersmann J. (2023). Recurrent disability progression endpoints in multiple sclerosis clinical trials.
Bühler A, Wolbers M, Model F, Wang Q, Belachew S, Manfrini M, Lorscheider J, Multiple Sclerosis (Houndmills, Basingstoke, England), 29(1), 130–139. https://doi.org/10.1177/13524585221125382
, & Beyersmann J. (2023). Recurrent disability progression endpoints in multiple sclerosis clinical trials.
Callegari, Ilaria, Schneider, Mika, Aebischer, Vera, Voortman, Margarete M., Proschmann, Undine, Ziemssen, Tjalf, Lindberg, Raija, Fischer-Barnicol, Bettina, Khalil, Michael, Therapeutic Advances in Neurological Disorders, 16. https://doi.org/10.1177/17562864221150040
, Kuhle, Jens, Sanderson, Nicholas S.R., & Derfuss, Tobias. (2023). Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
Callegari, Ilaria, Schneider, Mika, Aebischer, Vera, Voortman, Margarete M., Proschmann, Undine, Ziemssen, Tjalf, Lindberg, Raija, Fischer-Barnicol, Bettina, Khalil, Michael, Therapeutic Advances in Neurological Disorders, 16. https://doi.org/10.1177/17562864221150040
, Kuhle, Jens, Sanderson, Nicholas S.R., & Derfuss, Tobias. (2023). Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
Cerdá-Fuertes, Nuria, Nagy, Sara, Schaedelin, Sabine, Sinnecker, Tim, Ruberte, Esther, Papadopoulou, Athina, Würfel, Jens, Kuhle, Jens, Yaldizli, Özgür, Therapeutic Advances in Neurological Disorders, 16. https://doi.org/10.1177/17562864221150312
, Derfuss, Tobias, & Décard, Bernhard F. (2023). Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.
Cerdá-Fuertes, Nuria, Nagy, Sara, Schaedelin, Sabine, Sinnecker, Tim, Ruberte, Esther, Papadopoulou, Athina, Würfel, Jens, Kuhle, Jens, Yaldizli, Özgür, Therapeutic Advances in Neurological Disorders, 16. https://doi.org/10.1177/17562864221150312
, Derfuss, Tobias, & Décard, Bernhard F. (2023). Evaluation of frequency, severity, and independent risk factors for recurrence of disease activity after fingolimod discontinuation in a large real-world cohort of patients with multiple sclerosis.
Cerdá-Fuertes, Nuria, Stoessel, Marc, Mickeliunas, Gintaras, Pless, Silvan, Cagol, Alessandro, Barakovic, Muhamed, Maceski, Aleksandra Maleska, Álvarez González, Cesar, D’ Souza, Marcus, Schaedlin, Sabine, Benkert, Pascal, Calabrese, Pasquale, Gugleta, Konstantin, Derfuss, Tobias, Sprenger, Till, Granziera, Cristina, Naegelin, Yvonne, Multiple Sclerosis Journal, 29, 1540–1550. https://doi.org/10.1177/13524585231198760
, , et al. (2023). Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
Cerdá-Fuertes, Nuria, Stoessel, Marc, Mickeliunas, Gintaras, Pless, Silvan, Cagol, Alessandro, Barakovic, Muhamed, Maceski, Aleksandra Maleska, Álvarez González, Cesar, D’ Souza, Marcus, Schaedlin, Sabine, Benkert, Pascal, Calabrese, Pasquale, Gugleta, Konstantin, Derfuss, Tobias, Sprenger, Till, Granziera, Cristina, Naegelin, Yvonne, Multiple Sclerosis Journal, 29, 1540–1550. https://doi.org/10.1177/13524585231198760
, , et al. (2023). Optical coherence tomography versus other biomarkers: Associations with physical and cognitive disability in multiple sclerosis.
Chen, Xinjie, Schädelin, Sabine, Lu, Po-Jui, Ocampo-Pineda, Mario, Weigel, Matthias, Barakovic, Muhamed, Ruberte, Esther, Cagol, Alessandro, Marechal, Benedicte, Kober, Tobias, Kuhle, Jens, NeuroImage: Clinical, 37. https://doi.org/10.1016/j.nicl.2023.103349
, Melie-Garcia, Lester, & Granziera, Cristina. (2023). Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients.
Chen, Xinjie, Schädelin, Sabine, Lu, Po-Jui, Ocampo-Pineda, Mario, Weigel, Matthias, Barakovic, Muhamed, Ruberte, Esther, Cagol, Alessandro, Marechal, Benedicte, Kober, Tobias, Kuhle, Jens, NeuroImage: Clinical, 37. https://doi.org/10.1016/j.nicl.2023.103349
, Melie-Garcia, Lester, & Granziera, Cristina. (2023). Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients.
Galbusera, Riccardo, Bahn, Erik, Weigel, Matthias, Schaedelin, Sabine, Franz, Jonas, Lu, Po-Jui, Barakovic, Muhamed, Melie-Garcia, Lester, Dechent, Peter, Lutti, Antoine, Sati, Pascal, Reich, Daniel S., Nair, Govind, Brück, Wolfgang, Brain Pathology, 33. https://doi.org/10.1111/bpa.13136
, Stadelmann, Christine, & Granziera, Cristina. (2023). Postmortem quantitative MRI disentangles histological lesion types in multiple sclerosis.
Galbusera, Riccardo, Bahn, Erik, Weigel, Matthias, Schaedelin, Sabine, Franz, Jonas, Lu, Po-Jui, Barakovic, Muhamed, Melie-Garcia, Lester, Dechent, Peter, Lutti, Antoine, Sati, Pascal, Reich, Daniel S., Nair, Govind, Brück, Wolfgang, Brain Pathology, 33. https://doi.org/10.1111/bpa.13136
, Stadelmann, Christine, & Granziera, Cristina. (2023). Postmortem quantitative MRI disentangles histological lesion types in multiple sclerosis.
Gentile G., Mattiesing R.M., Brouwer I., van Schijndel R.A., Uitdehaag B.M.J., Twisk J.W.R., NeuroImage: Clinical, 38. https://doi.org/10.1016/j.nicl.2023.103397
, Freedman M.S., Comi G., Jack D., Barkhof F., De Stefano N., Vrenken H., & Battaglini M. (2023). The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.
Gentile G., Mattiesing R.M., Brouwer I., van Schijndel R.A., Uitdehaag B.M.J., Twisk J.W.R., NeuroImage: Clinical, 38. https://doi.org/10.1016/j.nicl.2023.103397
, Freedman M.S., Comi G., Jack D., Barkhof F., De Stefano N., Vrenken H., & Battaglini M. (2023). The spatio-temporal relationship between concurrent lesion and brain atrophy changes in early multiple sclerosis: A post-hoc analysis of the REFLEXION study.
Granziera, Cristina, Derfuss, Tobias, & JAMA Neurology, 80, 128–130. https://doi.org/10.1001/jamaneurol.2022.4156
. (2023). Time to Change the Current Clinical Classification of Multiple Sclerosis?
Granziera, Cristina, Derfuss, Tobias, & JAMA Neurology, 80, 128–130. https://doi.org/10.1001/jamaneurol.2022.4156
. (2023). Time to Change the Current Clinical Classification of Multiple Sclerosis?
Harding-Forrester, Sam, Roos, Izanne, Nguyen, Ai-Lan, Malpas, Charles B, Diouf, Ibrahima, Moradi, Nahid, Sharmin, Sifat, Izquierdo, Guillermo, Eichau, Sara, Patti, Francesco, Horakova, Dana, Kubala Havrdova, Eva, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand’Maison, Francois, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, et al. (2023). Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 94, 707–717. https://doi.org/10.1136/jnnp-2022-330726
Harding-Forrester, Sam, Roos, Izanne, Nguyen, Ai-Lan, Malpas, Charles B, Diouf, Ibrahima, Moradi, Nahid, Sharmin, Sifat, Izquierdo, Guillermo, Eichau, Sara, Patti, Francesco, Horakova, Dana, Kubala Havrdova, Eva, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grand’Maison, Francois, Onofrj, Marco, Lugaresi, Alessandra, Grammond, Pierre, et al. (2023). Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 94, 707–717. https://doi.org/10.1136/jnnp-2022-330726
Multiple Sclerosis Journal, 29(1), 6–7. https://doi.org/10.1177/13524585221139153
, Barkhof F., & Uitdehaag B. (2023). Otto van Eikema Hommes – 7 February 1932 – 16 August 2022.
Multiple Sclerosis Journal, 29(1), 6–7. https://doi.org/10.1177/13524585221139153
, Barkhof F., & Uitdehaag B. (2023). Otto van Eikema Hommes – 7 February 1932 – 16 August 2022.
Meier, Stephanie, Willemse, Eline A.J., Schaedelin, Sabine, Oechtering, Johanna, Lorscheider, Johannes, Melie-Garcia, Lester, Cagol, Alessandro, Barakovic, Muhamed, Galbusera, Riccardo, Subramaniam, Suvitha, Barro, Christian, Abdelhak, Ahmed, Thebault, Simon, Achtnichts, Lutz, Lalive, Patrice, Müller, Stefanie, Pot, Caroline, Salmen, Anke, Disanto, Giulio, et al. (2023). Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurology, 80, 287–297. https://doi.org/10.1001/jamaneurol.2022.5250
Meier, Stephanie, Willemse, Eline A.J., Schaedelin, Sabine, Oechtering, Johanna, Lorscheider, Johannes, Melie-Garcia, Lester, Cagol, Alessandro, Barakovic, Muhamed, Galbusera, Riccardo, Subramaniam, Suvitha, Barro, Christian, Abdelhak, Ahmed, Thebault, Simon, Achtnichts, Lutz, Lalive, Patrice, Müller, Stefanie, Pot, Caroline, Salmen, Anke, Disanto, Giulio, et al. (2023). Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurology, 80, 287–297. https://doi.org/10.1001/jamaneurol.2022.5250
Müller, Jannis, Cagol, Alessandro, Lorscheider, Johannes, Tsagkas, Charidimos, Benkert, Pascal, Yaldizli, Özgür, Kuhle, Jens, Derfuss, Tobias, Sormani, Maria Pia, Thompson, Alan, Granziera, Cristina, & JAMA Neurology, 80, 1232–1245. https://doi.org/10.1001/jamaneurol.2023.3331
. (2023). Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review.
Müller, Jannis, Cagol, Alessandro, Lorscheider, Johannes, Tsagkas, Charidimos, Benkert, Pascal, Yaldizli, Özgür, Kuhle, Jens, Derfuss, Tobias, Sormani, Maria Pia, Thompson, Alan, Granziera, Cristina, & JAMA Neurology, 80, 1232–1245. https://doi.org/10.1001/jamaneurol.2023.3331
. (2023). Harmonizing Definitions for Progression Independent of Relapse Activity inMultiple Sclerosis A Systematic Review.
Neziraj, Tradite, Med, 4(6), 344–346. https://doi.org/10.1016/j.medj.2023.05.006
, & Pröbstel, Anne-Katrin. (2023). Moving toward personalized B cell depletion in multiple sclerosis?
Neziraj, Tradite, Med, 4(6), 344–346. https://doi.org/10.1016/j.medj.2023.05.006
, & Pröbstel, Anne-Katrin. (2023). Moving toward personalized B cell depletion in multiple sclerosis?
Todea, Alexandra Ramona, Melie-Garcia, Lester, Barakovic, Muhamed, Cagol, Alessandro, Rahmanzadeh, Reza, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Ruberte, Esther, Radue, Ernst-Wilhelm, Schaedelin, Sabine, Benkert, Pascal, Oezguer, Yaldizli, Sinnecker, Tim, Müller, Stefanie, Achtnichts, Lutz, Vehoff, Jochen, Disanto, Giulio, Findling, Oliver, et al. (2023). A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. Journal of Magnetic Resonance Imaging, 58, 864–876. https://doi.org/10.1002/jmri.28618
Todea, Alexandra Ramona, Melie-Garcia, Lester, Barakovic, Muhamed, Cagol, Alessandro, Rahmanzadeh, Reza, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Ruberte, Esther, Radue, Ernst-Wilhelm, Schaedelin, Sabine, Benkert, Pascal, Oezguer, Yaldizli, Sinnecker, Tim, Müller, Stefanie, Achtnichts, Lutz, Vehoff, Jochen, Disanto, Giulio, Findling, Oliver, et al. (2023). A Multicenter Longitudinal MRI Study Assessing LeMan-PV Software Accuracy in the Detection of White Matter Lesions in Multiple Sclerosis Patients. Journal of Magnetic Resonance Imaging, 58, 864–876. https://doi.org/10.1002/jmri.28618
Tsagkas, Charidimos, Huck-Horvath, Antal, Cagol, Alessandro, Haas, Tanja, Barakovic, Muhamed, Amann, Michael, Ruberte, Esther, Melie-Garcia, Lester, Weigel, Matthias, Pezold, Simon, Schlaeger, Regina, Kuhle, Jens, Sprenger, Till, Multiple Sclerosis Journal, 29, 702–718. https://doi.org/10.1177/13524585221139152
, Bieri, Oliver, Cattin, Philippe, Granziera, Cristina, & Parmar, Katrin. (2023). Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
Tsagkas, Charidimos, Huck-Horvath, Antal, Cagol, Alessandro, Haas, Tanja, Barakovic, Muhamed, Amann, Michael, Ruberte, Esther, Melie-Garcia, Lester, Weigel, Matthias, Pezold, Simon, Schlaeger, Regina, Kuhle, Jens, Sprenger, Till, Multiple Sclerosis Journal, 29, 702–718. https://doi.org/10.1177/13524585221139152
, Bieri, Oliver, Cattin, Philippe, Granziera, Cristina, & Parmar, Katrin. (2023). Anterior horn atrophy in the cervical spinal cord: A new biomarker in progressive multiple sclerosis.
van Munster, Caspar E.P., Burggraaff, Jessica, Steinheimer, Saskia, Kamm, Christian P., D’Souza, Marcus, Diederich, Manuela, Dorn, Jonas, Walsh, Lorcan, Dahlke, Frank, International Journal of MS Care, 25, 226–232. https://doi.org/10.7224/1537-2073.2021-069
, & Uitdehaag, Bernard M.J. (2023). Assessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients With Multiple Sclerosis.
van Munster, Caspar E.P., Burggraaff, Jessica, Steinheimer, Saskia, Kamm, Christian P., D’Souza, Marcus, Diederich, Manuela, Dorn, Jonas, Walsh, Lorcan, Dahlke, Frank, International Journal of MS Care, 25, 226–232. https://doi.org/10.7224/1537-2073.2021-069
, & Uitdehaag, Bernard M.J. (2023). Assessment of Multiple Aspects of Upper Extremity Function Independent From Ambulation in Patients With Multiple Sclerosis.
Wenger A.L., Barakovic, Muhamed, Bosticardo, Sara, Schaedelin, Sabine, Daducci, Alessandro, Schiavi, Simona, Weigel, Matthias, Rahmanzadeh, Reza, Lu, Po-Jui, Cagol, Alessandro, Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.1007580
, Kuhle, Jens, Calabrese, Pasquale, & Granziera, Cristina. (2023). An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis.
Wenger A.L., Barakovic, Muhamed, Bosticardo, Sara, Schaedelin, Sabine, Daducci, Alessandro, Schiavi, Simona, Weigel, Matthias, Rahmanzadeh, Reza, Lu, Po-Jui, Cagol, Alessandro, Frontiers in Neuroscience, 17. https://doi.org/10.3389/fnins.2023.1007580
, Kuhle, Jens, Calabrese, Pasquale, & Granziera, Cristina. (2023). An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis.
Wilson, David, Chan, Dandan, Chang, Lei, Mathis, Robert, Verberk, Inge, Montalban, Xavier, Comabella, Manuel, Fissolo, Nicolas, Bielekova, Bibi, Masvekar, Ruturaj, Chitnis, Tanuja, Ziemssen, Tjalf, Akgün, Katja, Blennow, Kaj, Zetterberg, Henrik, Brück, Wolfgang, Giovannoni, Gavin, Gnanapavan, Sharmilee, Bittner, Stefan, et al. (2023). Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: Toward a clinical blood test for neuronal injury. Clinical Chemistry and Laboratory Medicine, null. https://doi.org/10.1515/cclm-2023-0518
Wilson, David, Chan, Dandan, Chang, Lei, Mathis, Robert, Verberk, Inge, Montalban, Xavier, Comabella, Manuel, Fissolo, Nicolas, Bielekova, Bibi, Masvekar, Ruturaj, Chitnis, Tanuja, Ziemssen, Tjalf, Akgün, Katja, Blennow, Kaj, Zetterberg, Henrik, Brück, Wolfgang, Giovannoni, Gavin, Gnanapavan, Sharmilee, Bittner, Stefan, et al. (2023). Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: Toward a clinical blood test for neuronal injury. Clinical Chemistry and Laboratory Medicine, null. https://doi.org/10.1515/cclm-2023-0518
Woelfle, Tim, Pless, Silvan, Reyes, Óscar, Wiencierz, Andrea, Multiple Sclerosis and Related Disorders, 80. https://doi.org/10.1016/j.msard.2023.105104
, Granziera, Cristina, & Lorscheider, Johannes. (2023). Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity.
Woelfle, Tim, Pless, Silvan, Reyes, Óscar, Wiencierz, Andrea, Multiple Sclerosis and Related Disorders, 80. https://doi.org/10.1016/j.msard.2023.105104
, Granziera, Cristina, & Lorscheider, Johannes. (2023). Smartwatch-derived sleep and heart rate measures complement step counts in explaining established metrics of MS severity.
Woelfle T, Pless S, Reyes O, Wiencierz A, Feinstein A, Calabrese P, Gugleta K, Journal of Neurology, 270(1), 262–271. https://doi.org/10.1007/s00415-022-11306-5
, Lorscheider J, & Naegelin Y. (2023). Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
Woelfle T, Pless S, Reyes O, Wiencierz A, Feinstein A, Calabrese P, Gugleta K, Journal of Neurology, 270(1), 262–271. https://doi.org/10.1007/s00415-022-11306-5
, Lorscheider J, & Naegelin Y. (2023). Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study.
Chang I, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(14), 2263–2273. https://doi.org/10.1177/13524585221114997
, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, & Zhu B. (2022). Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Chang I, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(14), 2263–2273. https://doi.org/10.1177/13524585221114997
, Giovannoni G, Calabresi PA, Sandrock A, Cheng W, Xiao S, Riester K, Belachew S, Deykin A, & Zhu B. (2022). Overall Disability Response Score: An integrated endpoint to assess disability improvement and worsening over time in patients with multiple sclerosis.
Meaton I, Altokhis A, Allen CM, Clarke MA, Sinnecker T, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Granziera C, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(14), 2212–2220. https://doi.org/10.1177/13524585221118677
, Montalban X, Rovira À, et al. (2022). Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
Meaton I, Altokhis A, Allen CM, Clarke MA, Sinnecker T, Meier D, Enzinger C, Calabrese M, De Stefano N, Pitiot A, Giorgio A, Schoonheim MM, Paul F, Pawlak MA, Schmidt R, Granziera C, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(14), 2212–2220. https://doi.org/10.1177/13524585221118677
, Montalban X, Rovira À, et al. (2022). Paramagnetic rims are a promising diagnostic imaging biomarker in multiple sclerosis.
Woelfle, T., Bourguignon, L., Lorscheider, J., Kappos, L., Naegelin, Y., & Jutzeler, C. R. (2022, November 18). Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective (Preprint) [Posted-content]. JMIR Publications Inc. https://doi.org/10.2196/preprints.44428
Woelfle, T., Bourguignon, L., Lorscheider, J., Kappos, L., Naegelin, Y., & Jutzeler, C. R. (2022, November 18). Wearable Sensor Technologies to Assess Motor Functions in People With Multiple Sclerosis: Systematic Scoping Review and Perspective (Preprint) [Posted-content]. JMIR Publications Inc. https://doi.org/10.2196/preprints.44428
Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, et al. (2022). Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 99(17), e1926–e1944. https://doi.org/10.1212/wnl.0000000000201029
Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, et al. (2022). Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology, 99(17), e1926–e1944. https://doi.org/10.1212/wnl.0000000000201029
Leppert D, Kropshofer H, Häring D, Dahlke F, Patil A, Meinert R, Tomic D, Neurology, 99(14), 631. https://doi.org/10.1212/wnl.0000000000201277
, & Kuhle J. (2022). Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D, Kropshofer H, Häring D, Dahlke F, Patil A, Meinert R, Tomic D, Neurology, 99(14), 631. https://doi.org/10.1212/wnl.0000000000201277
, & Kuhle J. (2022). Author Response: Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Arnold, Douglas L, Sprenger, Till, Bar-Or, Amit, Wolinsky, Jerry S, Multiple Sclerosis Journal, 28(12), 1927–1936. https://doi.org/10.1177/13524585221097561
, Kolind, Shannon, Bonati, Ulrike, Magon, Stefano, van Beek, Johan, Koendgen, Harold, Bortolami, Oscar, Bernasconi, Corrado, Gaetano, Laura, & Traboulsee, Anthony. (2022). Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS [Journal-article].
Arnold, Douglas L, Sprenger, Till, Bar-Or, Amit, Wolinsky, Jerry S, Multiple Sclerosis Journal, 28(12), 1927–1936. https://doi.org/10.1177/13524585221097561
, Kolind, Shannon, Bonati, Ulrike, Magon, Stefano, van Beek, Johan, Koendgen, Harold, Bortolami, Oscar, Bernasconi, Corrado, Gaetano, Laura, & Traboulsee, Anthony. (2022). Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS [Journal-article].
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(12), 1944–1962. https://doi.org/10.1177/13524585221102584
, & Cohen JA. (2022). Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Cree BA, Selmaj KW, Steinman L, Comi G, Bar-Or A, Arnold DL, Hartung HP, Montalbán X, Havrdová EK, Sheffield JK, Minton N, Cheng CY, Silva D, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(12), 1944–1962. https://doi.org/10.1177/13524585221102584
, & Cohen JA. (2022). Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial.
Kalincik T, Kister I, Bacon TE, Malpas CB, Sharmin S, Horakova D, Kubala-Havrdova E, Patti F, Izquierdo G, Eichau S, Ozakbas S, Onofrj M, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Sola P, Ferraro D, et al. (2022). Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(11), 1752–1761. https://doi.org/10.1177/13524585221084577
Kalincik T, Kister I, Bacon TE, Malpas CB, Sharmin S, Horakova D, Kubala-Havrdova E, Patti F, Izquierdo G, Eichau S, Ozakbas S, Onofrj M, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Sola P, Ferraro D, et al. (2022). Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(11), 1752–1761. https://doi.org/10.1177/13524585221084577
Sprenger T, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(11), 1719–1728. https://doi.org/10.1177/13524585221089534
, Sormani MP, Miller AE, Poole EM, Cavalier S, & Wuerfel J. (2022). Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
Sprenger T, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(11), 1719–1728. https://doi.org/10.1177/13524585221089534
, Sormani MP, Miller AE, Poole EM, Cavalier S, & Wuerfel J. (2022). Effects of teriflunomide treatment on cognitive performance and brain volume in patients with relapsing multiple sclerosis: Post hoc analysis of the TEMSO core and extension studies.
Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P, Arnould S, Dahlke F, Hach T, Ritter S, Karlsson G, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1526–1540. https://doi.org/10.1177/13524585221076717
, Fox RJ, & EXPAND Clinical Investigators. (2022). Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Arnold DL, Piani-Meier D, Bar-Or A, Benedict RH, Cree BA, Giovannoni G, Gold R, Vermersch P, Arnould S, Dahlke F, Hach T, Ritter S, Karlsson G, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1526–1540. https://doi.org/10.1177/13524585221076717
, Fox RJ, & EXPAND Clinical Investigators. (2022). Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1591–1605. https://doi.org/10.1177/13524585221083194
. (2022). Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Cree BA, Arnold DL, Fox RJ, Gold R, Vermersch P, Benedict RH, Bar-Or A, Piani-Meier D, Rouyrre N, Ritter S, Kilaru A, Karlsson G, Giovannoni G, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1591–1605. https://doi.org/10.1177/13524585221083194
. (2022). Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1562–1575. https://doi.org/10.1177/13524585221078825
. (2022). Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gärtner J, Hauser SL, Bar-Or A, Montalban X, Cohen JA, Cross AH, Deiva K, Ganjgahi H, Häring DA, Li B, Pingili R, Ramanathan K, Su W, Willi R, Kieseier B, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1562–1575. https://doi.org/10.1177/13524585221078825
. (2022). Efficacy and safety of ofatumumab in recently diagnosed, treatment-naive patients with multiple sclerosis: Results from ASCLEPIOS I and II.
Gold R, Piani-Meier D, Journal of Neurology, 269(9), 5093–5104. https://doi.org/10.1007/s00415-022-11166-z
, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, & Cree BAC. (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Gold R, Piani-Meier D, Journal of Neurology, 269(9), 5093–5104. https://doi.org/10.1007/s00415-022-11166-z
, Bar-Or A, Vermersch P, Giovannoni G, Fox RJ, Arnold DL, Benedict RHB, Penner IK, Rouyrre N, Kilaru A, Karlsson G, Ritter S, Dahlke F, Hach T, & Cree BAC. (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1576–1590. https://doi.org/10.1177/13524585221079731
. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Hauser SL, Cross AH, Winthrop K, Wiendl H, Nicholas J, Meuth SG, Giacomini PS, Saccà F, Mancione L, Zielman R, Bagger M, Das Gupta A, Häring DA, Jehl V, Kieseier BC, Pingili R, Stoneman D, Su W, Willi R, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(10), 1576–1590. https://doi.org/10.1177/13524585221079731
. (2022). Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years.
Lam KH, van Munster CEP, D’Souza M, Steinheimer S, Kamm CP, Burggraaff J, Johnson M, Zaykov Y, Dorn J, Dahlke F, International Journal of MS Care, 24(5), 230–234. https://doi.org/10.7224/1537-2073.2021-044
, Killestein J, & Uitdehaag B. (2022). Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures.
Lam KH, van Munster CEP, D’Souza M, Steinheimer S, Kamm CP, Burggraaff J, Johnson M, Zaykov Y, Dorn J, Dahlke F, International Journal of MS Care, 24(5), 230–234. https://doi.org/10.7224/1537-2073.2021-044
, Killestein J, & Uitdehaag B. (2022). Improving Detection of Change in Motor Functioning in Multiple Sclerosis Using Video-Assisted Composite Measures.
Rahmanzadeh R, Galbusera R, Lu PJ, Bahn E, Weigel M, Barakovic M, Franz J, Nguyen TD, Spincemaille P, Schiavi S, Daducci A, La Rosa F, Absinta M, Sati P, Bach Cuadra M, Radue EW, Leppert D, Kuhle J, Annals of Neurology, 92(3), 486–502. https://doi.org/10.1002/ana.26441
, et al. (2022). A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis.
Rahmanzadeh R, Galbusera R, Lu PJ, Bahn E, Weigel M, Barakovic M, Franz J, Nguyen TD, Spincemaille P, Schiavi S, Daducci A, La Rosa F, Absinta M, Sati P, Bach Cuadra M, Radue EW, Leppert D, Kuhle J, Annals of Neurology, 92(3), 486–502. https://doi.org/10.1002/ana.26441
, et al. (2022). A New Advanced MRI Biomarker for Remyelinated Lesions in Multiple Sclerosis.
Granziera C, Woelfle T, & Nature Reviews. Neurology, 18(8), 445–446. https://doi.org/10.1038/s41582-022-00692-z
. (2022). Development and implementation of new diagnostic technologies in neurology.
Granziera C, Woelfle T, & Nature Reviews. Neurology, 18(8), 445–446. https://doi.org/10.1038/s41582-022-00692-z
. (2022). Development and implementation of new diagnostic technologies in neurology.
Parmar K, Fonov VS, Naegelin Y, Amann M, Wuerfel J., Collins D.L., Gaetano L., Magon S., Sprenger T, Cerebellum (London, England), 21(4), 632–646. https://doi.org/10.1007/s12311-021-01312-0
, Granziera C., & Tsagkas C. (2022). Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients.
Parmar K, Fonov VS, Naegelin Y, Amann M, Wuerfel J., Collins D.L., Gaetano L., Magon S., Sprenger T, Cerebellum (London, England), 21(4), 632–646. https://doi.org/10.1007/s12311-021-01312-0
, Granziera C., & Tsagkas C. (2022). Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients.
Sharmin S, Bovis F, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grand’Maison F, Grammond P, Sola P, Ferraro D, Terzi M, Gerlach O, et al. (2022). Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 29(8), 2321–2334. https://doi.org/10.1111/ene.15406
Sharmin S, Bovis F, Malpas C, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Trojano M, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grand’Maison F, Grammond P, Sola P, Ferraro D, Terzi M, Gerlach O, et al. (2022). Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 29(8), 2321–2334. https://doi.org/10.1111/ene.15406
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, et al. (2022). The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(9), 1424–1456. https://doi.org/10.1177/13524585211069068
Tur C, Dubessy AL, Otero-Romero S, Amato MP, Derfuss T, Di Pauli F, Iacobaeus E, Mycko M, Abboud H, Achiron A, Bellinvia A, Boyko A, Casanova JL, Clifford D, Dobson R, Farez MF, Filippi M, Fitzgerald KC, Fonderico M, et al. (2022). The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021. Multiple Sclerosis (Houndmills, Basingstoke, England), 28(9), 1424–1456. https://doi.org/10.1177/13524585211069068
Battaglini M, Vrenken H, Tappa Brocci R, Gentile G, Luchetti L, Versteeg A, Freedman MS, Uitdehaag BMJ, European Journal of Neurology, 29(7), 2024–2035. https://doi.org/10.1111/ene.15314
, Comi G, Seitzinger A, Jack D, Sormani MP, Barkhof F, & De Stefano N. (2022). Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Battaglini M, Vrenken H, Tappa Brocci R, Gentile G, Luchetti L, Versteeg A, Freedman MS, Uitdehaag BMJ, European Journal of Neurology, 29(7), 2024–2035. https://doi.org/10.1111/ene.15314
, Comi G, Seitzinger A, Jack D, Sormani MP, Barkhof F, & De Stefano N. (2022). Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta-1a.
Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(8), 1277–1285. https://doi.org/10.1177/13524585211061861
, Ascherio A, & Munger KL. (2022). Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Manuel Escobar J, Cortese M, Edan G, Freedman MS, Hartung HP, Montalbán X, Sandbrink R, Radü EW, Barkhof F, Wicklein EM, Multiple Sclerosis (Houndmills, Basingstoke, England), 28(8), 1277–1285. https://doi.org/10.1177/13524585211061861
, Ascherio A, & Munger KL. (2022). Body mass index as a predictor of MS activity and progression among participants in BENEFIT.
Leppert D, Kropshofer H, Häring DA, Dahlke F, Patil A, Meinert R, Tomic D, Neurology, 98(21), e2120–e2131. https://doi.org/10.1212/wnl.0000000000200258
, & Kuhle J. (2022). Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Leppert D, Kropshofer H, Häring DA, Dahlke F, Patil A, Meinert R, Tomic D, Neurology, 98(21), e2120–e2131. https://doi.org/10.1212/wnl.0000000000200258
, & Kuhle J. (2022). Blood Neurofilament Light in Progressive Multiple Sclerosis: Post Hoc Analysis of 2 Randomized Controlled Trials.
Müller J, Sinnecker T, Wendebourg MJ, Schläger R, Kuhle J, Schädelin S, Benkert P, Derfuss T, Cattin P, Jud C, Spiess F, Amann M, Lincke T, Barakovic M, Cagol A, Tsagkas C, Parmar K, Pröbstel AK, Reimann S, et al. (2022). Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis. Neurology(R) Neuroimmunology & Neuroinflammation, 9(3). https://doi.org/10.1212/nxi.0000000000001147
Müller J, Sinnecker T, Wendebourg MJ, Schläger R, Kuhle J, Schädelin S, Benkert P, Derfuss T, Cattin P, Jud C, Spiess F, Amann M, Lincke T, Barakovic M, Cagol A, Tsagkas C, Parmar K, Pröbstel AK, Reimann S, et al. (2022). Choroid Plexus Volume in Multiple Sclerosis vs Neuromyelitis Optica Spectrum Disorder: A Retrospective, Cross-sectional Analysis. Neurology(R) Neuroimmunology & Neuroinflammation, 9(3). https://doi.org/10.1212/nxi.0000000000001147
Wendebourg MJ, Weigel M, Richter L, Gocheva V, Hafner P, Orsini A.-L., Crepulja V, Schmidt S, Huck A., Oechtering J., Blatow M, Haas T., Granziera C, European Journal of Neurology, 29(5), 1435–1445. https://doi.org/10.1111/ene.15261
, Cattin P, Bieri O., Fischer D, & Schlaeger R. (2022). Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome.
Wendebourg MJ, Weigel M, Richter L, Gocheva V, Hafner P, Orsini A.-L., Crepulja V, Schmidt S, Huck A., Oechtering J., Blatow M, Haas T., Granziera C, European Journal of Neurology, 29(5), 1435–1445. https://doi.org/10.1111/ene.15261
, Cattin P, Bieri O., Fischer D, & Schlaeger R. (2022). Spinal cord gray matter atrophy is associated with functional decline in post-polio syndrome.
Butzkueven H., Spelman T., Horakova D., Hughes S., Solaro C., Izquierdo G., Kubala Havrdova E., Grand’Maison F., Prat A., Girard M., Hupperts R., Onofrj M., Lugaresi A., Taylor B., Giovannoni G., European Journal of Neurology, 29(4), 1082–1090. https://doi.org/10.1111/ene.14824
, Hauser S.L., Montalban X., Craveiro L., et al. (2022). Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.
Butzkueven H., Spelman T., Horakova D., Hughes S., Solaro C., Izquierdo G., Kubala Havrdova E., Grand’Maison F., Prat A., Girard M., Hupperts R., Onofrj M., Lugaresi A., Taylor B., Giovannoni G., European Journal of Neurology, 29(4), 1082–1090. https://doi.org/10.1111/ene.14824
, Hauser S.L., Montalban X., Craveiro L., et al. (2022). Risk of requiring a wheelchair in primary progressive multiple sclerosis: Data from the ORATORIO trial and the MSBase registry.
Giovannoni G., European Journal of Neurology, 29(4), 1238–1242. https://doi.org/10.1111/ene.14823
, de Seze J., Hauser S.L., Overell J., Koendgen H., Manfrini M., Wang Q., & Wolinsky J.S. (2022). Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Giovannoni G., European Journal of Neurology, 29(4), 1238–1242. https://doi.org/10.1111/ene.14823
, de Seze J., Hauser S.L., Overell J., Koendgen H., Manfrini M., Wang Q., & Wolinsky J.S. (2022). Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Gold R., Arnold D.L., Bar-Or A., Fox R.J., Multiple Sclerosis Journal, 28(5), 801–816. https://doi.org/10.1177/13524585211037909
, Mokliatchouk O., Jiang X., Lyons J., Kapadia S., & Miller C. (2022). Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Gold R., Arnold D.L., Bar-Or A., Fox R.J., Multiple Sclerosis Journal, 28(5), 801–816. https://doi.org/10.1177/13524585211037909
, Mokliatchouk O., Jiang X., Lyons J., Kapadia S., & Miller C. (2022). Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results.
Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, Rӧsch N, Kaiser C, Mitchell CP, Leppert D, Havari E, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(4), 573–582. https://doi.org/10.1177/13524585211032348
. (2022). Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Kuhle J, Daizadeh N, Benkert P, Maceski A, Barro C, Michalak Z, Sormani MP, Godin J, Shankara S, Samad TA, Jacobs A, Chung L, Rӧsch N, Kaiser C, Mitchell CP, Leppert D, Havari E, & Multiple Sclerosis (Houndmills, Basingstoke, England), 28(4), 573–582. https://doi.org/10.1177/13524585211032348
. (2022). Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing-remitting MS.
Malpas CB, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H, Clinical Drug Investigation, 42(4), 355–364. https://doi.org/10.1007/s40261-022-01129-7
, Patti F, Alroughani R, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Hodgkinson S, Grammond P, Lechner-Scott J, Kalincik T, & MSBase Study Group. (2022). Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Malpas CB, Roos I, Sharmin S, Buzzard K, Skibina O, Butzkueven H, Clinical Drug Investigation, 42(4), 355–364. https://doi.org/10.1007/s40261-022-01129-7
, Patti F, Alroughani R, Horakova D, Havrdova EK, Izquierdo G, Eichau S, Hodgkinson S, Grammond P, Lechner-Scott J, Kalincik T, & MSBase Study Group. (2022). Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Schiavi S, Lu PJ, Weigel M, Lutti A, Jones DK, NeuroImage, 249, 118922. https://doi.org/10.1016/j.neuroimage.2022.118922
, Granziera C, & Daducci A. (2022). Bundle myelin fraction (BMF) mapping of different white matter connections using microstructure informed tractography.
Schiavi S, Lu PJ, Weigel M, Lutti A, Jones DK, NeuroImage, 249, 118922. https://doi.org/10.1016/j.neuroimage.2022.118922
, Granziera C, & Daducci A. (2022). Bundle myelin fraction (BMF) mapping of different white matter connections using microstructure informed tractography.
Zandl-Lang M, Züllig T, Trötzmüller M, Naegelin Y, Abela L, Wilken B, Scholl-Buergi S, Karall D, Metabolites, 12(4). https://doi.org/10.3390/metabo12040291
, Köfeler H, & Plecko B. (2022). Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome.
Zandl-Lang M, Züllig T, Trötzmüller M, Naegelin Y, Abela L, Wilken B, Scholl-Buergi S, Karall D, Metabolites, 12(4). https://doi.org/10.3390/metabo12040291
, Köfeler H, & Plecko B. (2022). Changes in the Cerebrospinal Fluid and Plasma Lipidome in Patients with Rett Syndrome.
Kropshofer H, Häring DA, Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. (Patent No. 11). 98(11), Article 11. https://doi.org/10.1212/wnl.0000000000200132
, Leppert D, & Kuhle J. (2022).
Kropshofer H, Häring DA, Reader Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. (Patent No. 11). 98(11), Article 11. https://doi.org/10.1212/wnl.0000000000200132
, Leppert D, & Kuhle J. (2022).
Bosticardo S, Schiavi S, Schaedelin S, Lu PJ, Barakovic M, Weigel M, Brain Connectivity, 12(1), 6–17. https://doi.org/10.1089/brain.2021.0047
, Kuhle J, Daducci A, & Granziera C. (2022). Microstructure-Weighted Connectomics in Multiple Sclerosis.
Bosticardo S, Schiavi S, Schaedelin S, Lu PJ, Barakovic M, Weigel M, Brain Connectivity, 12(1), 6–17. https://doi.org/10.1089/brain.2021.0047
, Kuhle J, Daducci A, & Granziera C. (2022). Microstructure-Weighted Connectomics in Multiple Sclerosis.
Cagol, Alessandro, Schaedelin, Sabine, Barakovic, Muhamed, Benkert, Pascal, Todea, Ramona-Alexandra, Rahmanzadeh, Reza, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Melie-Garcia, Lester, Ruberte, Esther, Siebenborn, Nina, Battaglini, Marco, Radue, Ernst-Wilhelm, Yaldizli, Özgür, Oechtering, Johanna, Sinnecker, Tim, Lorscheider, Johannes, Fischer-Barnicol, Bettina, et al. (2022). Association of Brain Atrophy with Disease Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis. JAMA Neurology, 79, 682–692. https://doi.org/10.1001/jamaneurol.2022.1025
Cagol, Alessandro, Schaedelin, Sabine, Barakovic, Muhamed, Benkert, Pascal, Todea, Ramona-Alexandra, Rahmanzadeh, Reza, Galbusera, Riccardo, Lu, Po-Jui, Weigel, Matthias, Melie-Garcia, Lester, Ruberte, Esther, Siebenborn, Nina, Battaglini, Marco, Radue, Ernst-Wilhelm, Yaldizli, Özgür, Oechtering, Johanna, Sinnecker, Tim, Lorscheider, Johannes, Fischer-Barnicol, Bettina, et al. (2022). Association of Brain Atrophy with Disease Progression Independent of Relapse Activity in Patients with Relapsing Multiple Sclerosis. JAMA Neurology, 79, 682–692. https://doi.org/10.1001/jamaneurol.2022.1025
De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]. 213, 106479. https://doi.org/10.1016/j.cmpb.2021.106479
, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand’Maison F, et al. (2022).
De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Corrigendum to Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression: [Computer Methods and Programs in Biomedicine, Volume 208, (September 2021) 106180]. 213, 106479. https://doi.org/10.1016/j.cmpb.2021.106479
, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand’Maison F, et al. (2022).
Diebold, Martin, Galli, Edoardo, Kopf, Andreas, Sanderson, Nicholas, Callegari, Ilaria, Ingelfinger, Florian, Núñez, Nicolás Gonzalo, Benkert, Pascal, Annals of Neurology, 91, 676–681. https://doi.org/10.1002/ana.26328
, Kuhle, Jens, Becher, Burkhard, Claassen, Manfred, & Derfuss, Tobias. (2022). Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
Diebold, Martin, Galli, Edoardo, Kopf, Andreas, Sanderson, Nicholas, Callegari, Ilaria, Ingelfinger, Florian, Núñez, Nicolás Gonzalo, Benkert, Pascal, Annals of Neurology, 91, 676–681. https://doi.org/10.1002/ana.26328
, Kuhle, Jens, Becher, Burkhard, Claassen, Manfred, & Derfuss, Tobias. (2022). Immunological Predictors of Dimethyl Fumarate-Induced Lymphopenia.
Diebold, Martin, Galli, Edoardo, Kopf, Andreas, Sanderson, Nicholas S.R., Callegari, Ilaria, Benkert, Pascal, Nuñez, Nicolas Gonzalo, Ingelfinger, Florian, Herms, Stefan, Cichon, Sven, Proceedings of the National Academy of Sciences of the United States of America, 119. https://doi.org/10.1073/pnas.2205042119
, Kuhle, Jens, Becher, Burkhard, Claassen, Manfred, & Derfuss, Tobias. (2022). High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.
Diebold, Martin, Galli, Edoardo, Kopf, Andreas, Sanderson, Nicholas S.R., Callegari, Ilaria, Benkert, Pascal, Nuñez, Nicolas Gonzalo, Ingelfinger, Florian, Herms, Stefan, Cichon, Sven, Proceedings of the National Academy of Sciences of the United States of America, 119. https://doi.org/10.1073/pnas.2205042119
, Kuhle, Jens, Becher, Burkhard, Claassen, Manfred, & Derfuss, Tobias. (2022). High-dimensional immune profiling identifies a biomarker to monitor dimethyl fumarate response in multiple sclerosis.
Diebold, Martin, Meola, Marco, Purushothaman, Srinithi, Siewert, Lena K, Pössnecker, Elisabeth, Roloff, Tim, Lindberg, Raija LP, Kuhle, Jens, Gut Microbes, 14. https://doi.org/10.1080/19490976.2022.2147055
, Derfuss, Tobias, Egli, Adrian, & Pröbstel, Anne-Katrin. (2022). Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis.
Diebold, Martin, Meola, Marco, Purushothaman, Srinithi, Siewert, Lena K, Pössnecker, Elisabeth, Roloff, Tim, Lindberg, Raija LP, Kuhle, Jens, Gut Microbes, 14. https://doi.org/10.1080/19490976.2022.2147055
, Derfuss, Tobias, Egli, Adrian, & Pröbstel, Anne-Katrin. (2022). Gut microbiota composition as a candidate risk factor for dimethyl fumarate-induced lymphopenia in multiple sclerosis.
Hardmeier, M., Hardmeier, M., Schlaeger, R., Lascano, A. M., Toffolet, L., Schindler, C., Gobbi, C., Lalive, P., Kuhle, J., Clinical neurophysiology, 137, 152–158. https://doi.org/10.1016/j.clinph.2022.02.019
, & Fuhr, P. (2022). Prognostic biomarkers in primary progressive multiple sclerosis: validating and scrutinizing multimodal evoked potentials.
Hardmeier, M., Hardmeier, M., Schlaeger, R., Lascano, A. M., Toffolet, L., Schindler, C., Gobbi, C., Lalive, P., Kuhle, J., Clinical neurophysiology, 137, 152–158. https://doi.org/10.1016/j.clinph.2022.02.019
, & Fuhr, P. (2022). Prognostic biomarkers in primary progressive multiple sclerosis: validating and scrutinizing multimodal evoked potentials.
Lokhande H, Rosso M., Tauhid S, Chu R, Healy BC, Saxena S, Barro C, Paul A, Polgar-Turcsanyi M, Anderson M., Glanz BI, Kropshofer H, Granziera C, Leppert D, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 8(1). https://doi.org/10.1177/20552173211069348
, Kuhle J., Weiner HL, Bakshi R., & Chitnis T. (2022). Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS.
Lokhande H, Rosso M., Tauhid S, Chu R, Healy BC, Saxena S, Barro C, Paul A, Polgar-Turcsanyi M, Anderson M., Glanz BI, Kropshofer H, Granziera C, Leppert D, Multiple Sclerosis Journal - Experimental, Translational and Clinical, 8(1). https://doi.org/10.1177/20552173211069348
, Kuhle J., Weiner HL, Bakshi R., & Chitnis T. (2022). Serum NfL levels in the first five years predict 10-year thalamic fraction in patients with MS.
Mattiesing RM, Gentile G, Brouwer I, van Schijndel RA, Uitdehaag BMJ, Twisk JWR, NeuroImage. Clinical, 36, 103220. https://doi.org/10.1016/j.nicl.2022.103220
, Freedman MS, Comi G, Jack D, De Stefano N, Barkhof F, Battaglini M, & Vrenken H. (2022). The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis.
Mattiesing RM, Gentile G, Brouwer I, van Schijndel RA, Uitdehaag BMJ, Twisk JWR, NeuroImage. Clinical, 36, 103220. https://doi.org/10.1016/j.nicl.2022.103220
, Freedman MS, Comi G, Jack D, De Stefano N, Barkhof F, Battaglini M, & Vrenken H. (2022). The spatio-temporal relationship between white matter lesion volume changes and brain atrophy in clinically isolated syndrome and early multiple sclerosis.